{
  "disease": "glioblastoma",
  "date_generated": "2026-02-14",
  "drugs_investigated": [
    "TALAMPANEL",
    "RIVOCERANIB",
    "GENISTEIN",
    "EDOTECARIN",
    "CEDIRANIB",
    "PERIFOSINE"
  ],
  "results": {
    "TALAMPANEL": {
      "total_failed_trials": 1,
      "classification": "UNKNOWN",
      "repurposing_viable": true,
      "safety_flags": 0,
      "trials": [
        {
          "nct_id": "NCT00062504",
          "title": "Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas",
          "status": "TERMINATED",
          "why_stopped": "Not specified",
          "failure_category": "UNKNOWN",
          "phases": ["PHASE2"],
          "conditions": [
            "Glioblastoma Multiforme",
            "Anaplastic Astrocytoma",
            "Anaplastic Oligodendroglioma",
            "Anaplastic Mixed Oligoastrocytoma"
          ]
        }
      ],
      "interpretation": "Phase 2 trial terminated without specified reason. No safety concerns mentioned. Candidate for repurposing."
    },
    "RIVOCERANIB": {
      "total_failed_trials": 0,
      "classification": "NONE",
      "repurposing_viable": true,
      "safety_flags": 0,
      "trials": [],
      "interpretation": "No glioblastoma trials found. Drug may have been dropped in other indications."
    },
    "GENISTEIN": {
      "total_failed_trials": 0,
      "classification": "NONE",
      "repurposing_viable": true,
      "safety_flags": 0,
      "trials": [],
      "interpretation": "No glioblastoma trials found. Drug may have been dropped in other indications."
    },
    "EDOTECARIN": {
      "total_failed_trials": 0,
      "classification": "NONE",
      "repurposing_viable": true,
      "safety_flags": 0,
      "trials": [],
      "interpretation": "No glioblastoma trials found. Drug may have been dropped in other indications."
    },
    "CEDIRANIB": {
      "total_failed_trials": 1,
      "classification": "BUSINESS/LOGISTICS",
      "repurposing_viable": true,
      "safety_flags": 0,
      "trials": [
        {
          "nct_id": "NCT01310855",
          "title": "Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma",
          "status": "TERMINATED",
          "why_stopped": "closed to recruitment early due to AstraZeneca not developing cediranib further",
          "failure_category": "BUSINESS/LOGISTICS",
          "phases": ["PHASE2"],
          "conditions": ["Glioblastoma"]
        }
      ],
      "interpretation": "PRIME REPURPOSING CANDIDATE. Phase 2 trial stopped solely due to corporate decision to cease drug development. No safety or efficacy concerns. This is the gold standard for repurposing."
    },
    "PERIFOSINE": {
      "total_failed_trials": 0,
      "classification": "NONE",
      "repurposing_viable": true,
      "safety_flags": 0,
      "trials": [],
      "interpretation": "No glioblastoma trials found. Drug may have been dropped in other indications."
    }
  },
  "summary": {
    "total_drugs": 6,
    "total_trials_found": 2,
    "business_dropouts": 1,
    "safety_dropouts": 0,
    "unknown_dropouts": 1,
    "prime_candidates": ["CEDIRANIB"],
    "key_finding": "CEDIRANIB is a gold-standard repurposing candidate: terminated Phase 2 glioblastoma trial due to corporate decision (AstraZeneca ceased development), not safety or efficacy."
  }
}
